Home Newsfeeds Credit Suisse Downgrades JELD-WEN Holding to Neutral

Credit Suisse Downgrades JELD-WEN Holding to Neutral

Credit Suisse analyst Daniel Oppenheim downgrades JELD-WEN Holding (NYSE:JELD) from Outperform to Neutral.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Credit Suisse analyst Daniel Oppenheim downgrades JELD-WEN Holding (NYSE:JELD) from Outperform to Neutral.

Cathie Wood Scooped Up $17M Worth Of Zoom Shares On A Day They Fell 8%

By Bhavik Nair

May 23, 10:32 PM

Cathie Wood-led ARK Investment Management bought over 267,000 shares of communications technology company Zoom Video Communications Inc (NASDAQ:ZM)…

ARKK

Morgan Stanley Downgrades Core Laboratories to Underweight, Announces $20 Price Target

By Benzinga Newsdesk

September 26, 6:17 AM

Morgan Stanley analyst Connor Lynagh downgrades Core Laboratories (NYSE:CLB) from Equal-Weight to Underweight and announces $20 price target.

CLB

Canadian Cannabis Producer Reports Revenue Spike And Improved Margins In Q2, But What About Net Loss?

By Jelena Martinovic

August 15, 2:07 PM

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced reported its interim second-quarter financial statements for the three months ending June 30, 2023.

AVCNF

Ozempic’s Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What’s Next?

By Vandana Singh

November 21, 4:30 PM

Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's production, which has experienced a

NVO

Credit Suisse Downgrades JELD-WEN Holding to Neutral

Related Posts

Cathie Wood Scooped Up $17M Worth Of Zoom Shares On A Day They Fell 8%

Morgan Stanley Downgrades Core Laboratories to Underweight, Announces $20 Price Target

Canadian Cannabis Producer Reports Revenue Spike And Improved Margins In Q2, But What About Net Loss?

Ozempic’s Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What’s Next?